Skip to main content

01.12.2018 | Research article | Ausgabe 1/2018 Open Access

BMC Cancer 1/2018

C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells

BMC Cancer > Ausgabe 1/2018
Wei Li, Ling Xu, Xiaofang Che, Haizhou Li, Ye Zhang, Na Song, Ti Wen, Kezuo Hou, Yi Yang, Lu Zhou, Xing Xin, Lu Xu, Xue Zeng, Sha Shi, Yunpeng Liu, Xiujuan Qu, Yuee Teng
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1186/​s12885-018-4387-5) contains supplementary material, which is available to authorized users.



Tamoxifen is a frontline therapy for estrogen receptor (ER)-positive breast cancer in premenopausal women. However, many patients develop resistance to tamoxifen, and the mechanism underlying tamoxifen resistance is not well understood. Here we examined whether ER-c-Src-HER2 complex formation is involved in tamoxifen resistance.


MTT and colony formation assays were used to measure cell viability and proliferation. Western blot was used to detect protein expression and protein complex formations were detected by immunoprecipitation and immunofluorescence. SiRNA was used to examine the function of HER2 in of BT474 cells. An in vivo xenograft animal model was established to examine the role of c-Cbl in tumor growth.


MTT and colony formation assay showed that BT474 cells are resistant to tamoxifen and T47D cells are sensitive to tamoxifen. Immunoprecipitation experiments revealed ER-c-Src-HER2 complex formation in BT474 cells but not in T47D cells. However, ER-c-Src-HER2 complex formation was detected after overexpressing HER2 in T47D cells and these cells were more resistant to tamoxifen. HER2 knockdown by siRNA in BT474 cells reduced ER-c-Src-HER2 complex formation and reversed tamoxifen resistance. ER-c-Src-HER2 complex formation was also disrupted and tamoxifen resistance was reversed in BT474 cells by the c-Src inhibitor PP2 and HER2 antibody trastuzumab. Nystatin, a lipid raft inhibitor, reduced ER-c-Src-HER2 complex formation and partially reversed tamoxifen resistance. ER-c-Src-HER2 complex formation was disrupted by overexpression of c-Cbl but not by the c-Cbl ubiquitin ligase mutant. In addition, c-Cbl could reverse tamoxifen resistance in BT474 cells, but the ubiquitin ligase mutant had no effect. The effect of c-Cbl was validated in BT474 tumor-bearing nude mice in vivo. Immunofluorescence also revealed ER-c-Src-HER2 complex formation was reduced in tumor tissues of nude mice with c-Cbl overexpression.


Our results suggested that c-Cbl can reverse tamoxifen resistance in HER2-overexpressing breast cancer cells by inhibiting the formation of the ER-c-Src-HER2 complex.
Additional file 1: Figure S1. Quantification of p-HER2 and p-ER blots in Fig. 7c. BT474 cells were transfected with control vector or c-Cbl overexpression plasmids for 24 h, followed by vehicle (CON), estrogen (10 nmol/L) (E2), tamoxifen (1 μmol/L) (TAM) or combination treatment (E2/TAM) for 4 h. (A) The relative density of phospho-HER2. *P < 0.05. (B) The relative density of phospho-ER. *P < 0.05. (JPG 799 kb)
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

BMC Cancer 1/2018 Zur Ausgabe